Spots Global Cancer Trial Database for A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Official Title: An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Study ID: NCT05276310
Conditions
Interventions
Study Description
Brief Summary: This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
Detailed Description: The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IMC-002. Multiple-dose levels of IMC-002 will be tested in subjects with advanced cancer.
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Asan Medical Center, Republic of Korea, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: HEUNG TAE KIM, MD
Affiliation: ImmuneOncia Therapeutics Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
